Clinical Trials Browser

Phase 1/2 × Colonic Neoplasms × ibrutinib × Clear all

NCT03332498 2022-06-03

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

Phase 1/2 Completed

40 enrolled 12 charts

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms